SEPN
Septerna Inc · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 518.59K | New | $11.88M | 0.0% | New | 1 | SEC ↗ ×2 |
| 2 | Citadel Advisors ✦ | 404.88K | New | $9.27M | 0.0% | New | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 380.58K | New | $8.72M | 0.0% | New | 1 | SEC ↗ ×2 |
| 4 | Adage Capital Partners ✦ | 300.00K | New | $6.87M | 0.0% | New | 1 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (passive) | 272.78K | n/a | $6.25M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Soros Fund Management ✦ | 10.00K | New | $229,000 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| T. Rowe Price | $11.88M | 0.0% |
| Citadel Advisors | $9.27M | 0.0% |
| Geode Capital Management | $8.72M | 0.0% |
| Adage Capital Partners | $6.87M | 0.0% |
| Soros Fund Management | $229,000 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 123 holders, 45.64M shares, $1.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.91K sh · $109,307
Officer · 1.09K sh · $40,337
10% owner · 141 sh · $7,202
Director, 10% owner · 746.50K sh · $31.73M
Director, 10% owner · 746.50K sh · $31.73M
10% owner · 147.06K sh · $7.39M
Officer · 25.00K sh · $1.10M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
11.8% of class · View original SEC filing ↗